天津医药

• 论著 • 上一篇    下一篇

肺舒胶囊治疗慢性阻塞性肺疾病稳定期临床观察

钟红卫1,彭素岚2,罗永兵2,高海燕3,敖素华2,王俊峰2   

  1. 1. 四川泸州医学院附属中医院
    2. 泸州医学院附属中医院
    3. 内蒙古鄂尔多斯市第二人民医院
  • 收稿日期:2010-03-04 修回日期:2010-05-30 出版日期:2010-10-15 发布日期:2010-10-15
  • 通讯作者: 钟红卫

The Clinical Effect Observation Of Feishu Capsule On The Steady Stage Period Of COPD

  • Received:2010-03-04 Revised:2010-05-30 Published:2010-10-15 Online:2010-10-15
  • Contact: zhonghongwei

PDF (PC)

2239

摘要： 观察肺舒胶囊(现更名为参蛤益肺胶囊,川药制字Z20080756)治疗慢性阻塞性肺疾病(COPD)稳定期患者的临床疗效。方法: 采用随机单盲研究方法将87例符合纳入标准的研究对象随机分成治疗组（44例）和对照组（43例）。观察两组在治疗前后的中医证候疗效；肺功能指标：第一秒呼气容积 (FEV1％ )，第一秒呼气容积与用力呼气量之比(FEV1／FVC)， BODE指数：体重指数（BMI），气流阻塞程度【O ，第1秒用力呼气容积占预计值百分比（FEV1%pred）】, 呼吸困难【D，功能性呼吸困难量表（MMRC）】，运动耐力【E，6min行走距离(6MWT)】。结果：中医证候疗效治疗组总有效率88．64％，对照组为67．44％ (P＜0.05)；肺功能（FEV1％、FEV1／FVC）治疗组治疗前后比较有差异(P＜0．05)，对照组治疗前后比较无差异(P>0．05)，治疗后两组比较有差异(P＜0．05)；BODE指数计分：治疗组前后比较有差异(P＜0．05)，对照组治疗前后无差异(P>0．05)，治疗后两组比较有差异(P＜0．05)。结论: 肺舒胶囊对COPD稳定期患者能增高患者的中医证候疗效，延缓肺功能下降，改善BODE指数, 提高患者的生存质量。

关键词: 肺舒胶囊, 慢性阻塞性肺疾病稳定期, 临床疗效, 肺功能, BODE指数

Abstract: Abstract：To observe the clinical effect of Feishu capsule which has been renamed Shengeyifei capsule（drug approval number Z20080756） on the steady stage period of COPD. Methods: With randomized, single blinded trial 87 patients with steady stage period of COPD were randomized divided in two groups. One is the cure group(44 cases) and the other is the control group(43 cases). Indexes evaluated were following: indexes (syndrome in TCM , pulmonary function, ratio of FEV1／FVC, BODE ,BMI, air current obstruct degree (O，FEV1%pred),dyspnea (D，MMRC))， movement resistance （E，6MWT）。Result: the effective rate of syndrome indexes in TCM is 88.64%,the control group is 67．44％ (P＜0.05)；pulmonary function （FEV1％、FEV1／FVC）were increased significantly after treatment compared with that before(P＜0．05) in cure group, there was no difference in control group(P>0．05). the cure group was elevated compared with the control group after the treatment (P＜0．05) ;BODE indexes were decreased significantly after treatment compared with that before(P＜0．05) in cure group, there was no difference in control group(P>0．05). the cure group was decreased compared with the control group after the treatment (P＜0．05)。Conclusion: The elemental research indicates Feishu capsule on the steady stage period of COPD has probably advantages in improvement of syndrome indexes in TCM, pulmonary function, BODE indexes and personal living ability.

Key words: Feishu capsule, the steady stage period of COPD, clinical effect, pulmonary function, BODE indexes